Overview of Development Pipeline of Melanocortins for Treatment of Ocular Conditions and Role in Resolving Inflammation
PL9643 Phase 3 Study Results in Dry Eye Disease Currently Expected 2Q 2023
Palatin Progressing Development Programs in Retinal and Front-of-the-Eye Indications Supported by Breakthrough Science
CRANBURY, N. J. , Sept. 29, 2022 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the particular melanocortin receptor system, announced that Paul Kayne, Ph. D., Vice President associated with Biological Sciences at Palatin, presented today at the [email protected] in Chicago, IL. The presentation was one of several in the ” [email protected] AAO 2022 – Therapeutics Showcase” general session.
Palatin’s presentation included an overview of its development pipeline of melanocortins with regard to inflammatory conditions, including several for ocular indications, plus a summary of the role associated with melanocortins within resolving inflammation. The presentation focused on Palatin’s research program with melanocortins in retinal disease, including genomics and proteomics data supporting the particular mechanism of action associated with melanocortins inside the resolution of swelling in retinal tissue.
Eyecelerator is a partnership between the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS). Its mission is to connect entrepreneurs, investors, companies, and physicians to advance ophthalmic innovation through live conferences, virtual programming, and a next-generation networking platform.
Palatin is currently conducting a Phase 3 clinical study with PL9643 in patients for the treatment of dry eye disease along with initial results expected in the second quarter associated with calendar year 2023. PL9643 is a novel melanocortin agonist, delivered to the eye topically via eyedrops. Palatin previously announced positive results in its Phase 2 study of PL9643 regarding the treatment of DED. Improvement in multiple signs plus symptoms has been achieved in the moderate in order to severe patient population after 2 weeks of dosing and at the particular 12-week visit. There were no safety signals identified and PL9643 had excellent ocular tolerability.
Palatin has a number of additional research programs intended for treatments associated with inflammatory problems, both ocular and non-ocular. These study programs include extensive studies on the genomics and proteomics supporting the mechanism of action plus role associated with melanocortins on the quality of irritation.
American School of Ophthalmology
The particular Academy is the world’s largest association of eye doctors and surgeons. A global community associated with 32, 000 medical doctors, it protects sight and empowers lives by setting the particular standards to get ophthalmic education and advocating for patients as well as the public. The Academy innovates to advance the profession and to ensure the particular delivery of the highest-quality vision care. Through its EyeSmart® articles upon AAO. org, the School provides the public with the most trusted information about attention health. For more information, visit aao. org.
ASCRS (American Community of Cataract and Refractive Surgery)
ASCRS is an international educational society along with nearly 8, 000 ophthalmic surgeons at every career stage. Its objective is in order to empower anterior segment cosmetic surgeons to improve the particular vision, outcomes, and quality of life for their individuals through innovative approaches to schooling, advocacy, and philanthropy. For more info, visit ascrs. org.
About Melanocortin Receptor Agonists plus Inflammation
The melanocortin receptor (“MCr”) system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, via use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have medically significant pharmacological effects.
Many tissues and immune cells located within the eye (and other places, pertaining to example the gut plus kidney) express melanocortin receptors, empowering our opportunity to directly activate natural pathways to resolve disease inflammation.
Palatin is really a biopharmaceutical company developing first-in-class medicines depending on molecules that will modulate the experience of the particular melanocortin receptor systems, with targeted, receptor-specific product candidates for that treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is in order to develop products and then form marketing collaborations along with industry leaders to maximize their commercial potential. With regard to additional details regarding Palatin, please check out Palatin’s website at www.Palatin.com plus follow Palatin on Twitter at @PalatinTech.
Claims in this press release that are not historical facts, which includes statements about future expectations of Palatin, such as statements regarding clinical trial plans and potential outcomes for PL9643, are “forward-looking statements” within the meaning of Section 27A from the Securities Act of 1933, Section 21E of the Securities Exchange Act associated with 1934 plus as that term will be defined within the Private Securities Litigation Reform Act of 1995. Palatin intends that will such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin’s actual results to become materially different from the historical results or from any outcomes expressed or implied simply by such forward-looking statements. Palatin’s actual results may differ materially from those discussed inside the forward-looking statements meant for reasons including, but not limited to, outcomes of medical trials, regulatory actions by the FDA along with other regulatory and the need designed for regulatory approvals, Palatin’s ability to fund development associated with its technology and establish and successfully complete scientific trials, the particular length of time and cost required to complete clinical trials plus submit applications for regulating approvals, items developed by competing pharmaceutical, biopharmaceutical and biotechnology businesses, commercial acceptance of Palatin’s products,
plus other aspects discussed in Palatin’s periodic filings with the Securities and Exchange Commission. Palatin is not responsible just for updating for the purpose of events that occur right after the date of this press release.
Palatin Technologies® plus Vyleesi® are registered trademarks of Palatin Technologies, Inc.
SOURCE Palatin Technologies, Incorporation.